Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.09), versus ($0.19) reported last year. Revenue for the quarter came in at $139 million, versus $512 million reported last year.
Based on current plans, the Company estimates that it has capital resources to reach beyond the final analysis of SEAMLESS and continue existing programs through the end of 2017.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Consensus Mining & Seigniorage Corporation (CMSG) Tops Q3 EPS by 331c
- Chain Bridge Bancorp, Inc. (CBNA) Tops Q3 EPS by 166c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
